EXPERT OPINION ON EMERGING DRUGS新兴药物专家意见
EXPERT OPINION ON EMERGING DRUGS(英文缩写 EXPERT OPIN EMERG DR),ISSN 1472-8214,eISSN 1744-7623,中文译名:新兴药物专家意见 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-09-27 至 2026-09-27，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 3.912 | Q2 |
| 2022 | 3.400 | Q2 |
| 2023 | 2.700 | Q2 |
| 2024 | 2.700 | Q2 |
| 2025 | 3.800 | Q2 |
EXPERT OPINION ON EMERGING DRUGS 最新收录文献
-
3. Recent advances in hidradenitis suppurativa therapeutics: a focus on existing and future medical therapeutics.
PMID:日期:2026-09-05HS is an inflammatory skin condition that causes abscesses, nodules, and tunnels in the intertriginous areas. Treatment consists of multimodal therapy such as topical and systemic antibiotics, topical washes and ointments, hormonal modulation, retinoids, surgery, and recently biologic therapy. The FDA approved 3 biologics for HS in the last 10 years, although novel options are needed for recalcitrant disease. A comprehensive search of the National Institutes of Health (NIH) Clinical Trials database was performed in April 2025, with an updated search performed in October 2025. Trials were limited to hidradenitis suppurativa, phase 2 or 3, and a status of not yet recruiting, recruiting, active, completed, or terminated. Data were supplemented with a query of PubMed and an internet search for topline data and press releases from companies. Our results include 52 phase 2 studies and 16 phase 3 studies. Biologics serve as a steppingstone to a new age of therapy for HS. Investigations are needed for recalcitrant disease, to minimize effects of adverse events, and provide personalized treatment. Compounds with promising results include JAK inhibitors, while other compounds await results, and others limited by small sample sizes and non-randomized study designs. Future trials should focus on comparative drug designs and ensuring fair trial access for all patients, particularly patients with the highest disease burden.
-
4. Emerging biological drugs for the treatment of patients with metastatic HER2+ gastroesophageal adenocarcinomas.
PMID:日期:2026-09-01Advanced gastroesophageal adenocarcinomas (GEAs) continue to represent an area in need of new drug development. Targeting human epidermal growth factor receptor-2 (HER2) in GEAs has been standard since 2010 and continues to be an area of further development. Trastuzumab became the first targeted agent approved for GEA. Added to front-line fluoropyrimidine plus platinum chemotherapy in HER2+ metastatic disease, trastuzumab improved survival. Pembrolizumab was approved in HER2 positive GEA for those PD-L1 positive with modest benefit. Since trastuzumab's approval, other anti-HER2 agents had limited impact until 2021 with the FDA approval of trastuzumab deruxtecan. Trastuzumab deruxtecan represents an option after trastuzumab-based therapy fails. Other agents are currently being investigated. With the abundance of anti-HER2 therapies in the investigative pipeline, understanding key resistance mechanisms seen in HER2+ GEA will be the path to success. Technology advancements to provide real‑time precision medicine are likely in the coming years. We hope these advancements can help combat and/or understand some of the intratumoral heterogeneity, HER2 expression changes, and tumor microenvironment resistance pathways seen in HER2+ GEA.
-
5. {"_":"σ receptor agonists: the new trend or an emerging therapeutic option?","sub":["1"]}
PMID:日期:2026-09-01该文献暂无摘要。
-
6. Obefazimod (ABX464) for moderate-to-severe Crohn's disease: clinical development of a novel oral therapeutic approach.
6. Obefazimod（ABX464）治疗中重度克罗恩病：一种新型口服治疗方法的临床开发PMID:日期:2026-09-01该文献暂无摘要。
-
7. Evaluating emerging amyloid-β centric drugs for the treatment of Alzheimer's disease.
7. 评估新出现的以淀粉样蛋白β为中心的治疗阿尔茨海默病的药物PMID:日期:2026-09-01The amyloid cascade hypothesis provided a compelling rationale for Alzheimer's disease (AD) drug development, but many amyloid-β (Aβ)-targeted agents failed to show benefit. The present review article evaluated emerging Aβ-directed therapies, focusing on mechanisms, clinical efficacy, safety, and regulatory progress. The recent approvals of lecanemab and donanemab offered the first convincing evidence that reducing Aβ burden can modestly slow cognitive decline in early AD. Beyond these first-generation monoclonal antibodies, the pipeline includes next-generation antibodies with enhanced brain penetration (trontinemab), therapies designed also for presymptomatic intervention (remternetug tested for secondary prevention), and novel approaches targeting galectin-3 to disrupt Aβ aggregation and neuroinflammation. Active immunotherapies like UB-311 and small molecules such as ALZ-801, avoiding amyloid-related imaging abnormalities (ARIA), broaden the therapeutic horizon with potentially safer and more accessible options, but with no proven efficacy. Clinical benefits for Aβ-centric therapies are modest, ARIA poses ongoing safety concerns, and high costs coupled with intensive monitoring limit accessibility. Regulators have begun to restrict approval to genetically defined subgroups according to apolipoprotein E genotype, underscoring the need for precision medicine. Therefore, while Aβ-centric therapies are incremental, they represent essential steps toward combination and precision strategies in the treatment of AD.
-
8. Emerging treatment options for chronic obstructive pulmonary disease: a look into 2026 and beyond.
PMID:日期:2026-09-01As a leading cause of worldwide mortality, chronic obstructive pulmonary disease (COPD) is progressive and irreversible, leading to significant challenges with disease management and treatment. This is further complicated by the heterogenous nature of COPD, which is represented by the multiple endotypes that have variable responses to available treatments, thereby negating the one-size-fits-all approach. While recent clinical studies describe the effectiveness of existing therapies, further investigation is required to align COPD endotypes with the appropriate treatment options. In this review, we discuss the known biomarkers pertaining to both direct and indirect measures of the inflammatory milieu and structural abnormalities in COPD. Combined use of conventional anti-inflammatory and bronchodilator treatments provide some symptomatic relief by reducing exacerbation frequency, however, for some patients, long-term corticosteroid use can increase the risk developing pneumonia and subsequent mortality. Biologics are at the forefront of emerging therapies for COPD, which shifts the target from widespread airway inflammation to pinpoint precise inflammatory markers involved in pathophysiological mechanisms of COPD. Identifying reliable airway-derived biomarkers in COPD will drive the development of therapies that can facilitate a precision medicine approach for patients with COPD.
-
9. Beyond triptans in menstrual migraine: the emerging role of CGRP-targeted therapies.
PMID:日期:2026-09-01Menstrual migraine is a common and disabling subtype of migraine, linked to hormonal fluctuations and characterized by attacks that are often more severe, longer lasting and less responsive to treatment than non-menstrual episodes. Despite its relevance, menstrual migraine remains underdiagnosed and undertreated. This review examines the role of therapies targeting the calcitonin gene-related peptide (CGRP) pathway in menstrual migraine. We summarize current evidence on monoclonal antibodies and gepants, focusing on their efficacy in hormonally triggered attacks and their potential advantages over traditional treatments. CGRP-targeted therapies represent a promising mechanism-based approach for menstrual migraine, although their role is not yet fully defined. These treatments reduce overall migraine burden, but the perimenstrual component may remain relatively resistant. The lack of dedicated clinical trials is a major limitation. Among available options, gepants offer the greatest potential due to their flexibility for both acute and short-term preventive use. Future research should focus on time-specific treatment strategies and a broader understanding of the underlying biology, including the role of additional neuropeptides.